Analysts Expect Elanco Animal Health (NYSE:ELAN) Will Post Earnings of $0.24 Per Share

Analysts expect Elanco Animal Health (NYSE:ELAN) to report $0.24 earnings per share (EPS) for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Elanco Animal Health’s earnings, with the highest EPS estimate coming in at $0.25 and the lowest estimate coming in at $0.23. Elanco Animal Health posted earnings of $0.29 per share during the same quarter last year, which suggests a negative year over year growth rate of 17.2%. The firm is expected to report its next quarterly earnings results on Wednesday, February 5th.

On average, analysts expect that Elanco Animal Health will report full-year earnings of $1.07 per share for the current year, with EPS estimates ranging from $1.05 to $1.08. For the next financial year, analysts anticipate that the firm will report earnings of $1.22 per share, with EPS estimates ranging from $1.18 to $1.30. Zacks’ earnings per share averages are an average based on a survey of sell-side analysts that cover Elanco Animal Health.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Wednesday, November 6th. The company reported $0.30 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.04. The company had revenue of $771.30 million during the quarter, compared to analyst estimates of $765.85 million. Elanco Animal Health had a return on equity of 7.79% and a net margin of 3.04%. Elanco Animal Health’s quarterly revenue was up 1.3% on a year-over-year basis. During the same period in the prior year, the company posted $0.29 earnings per share.

A number of research analysts have issued reports on the company. ValuEngine upgraded Elanco Animal Health from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. UBS Group lowered their target price on Elanco Animal Health from $30.00 to $28.00 and set a “neutral” rating on the stock in a research note on Wednesday, November 20th. Zacks Investment Research cut Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Tuesday, October 15th. Goldman Sachs Group started coverage on shares of Elanco Animal Health in a research report on Monday, September 9th. They set a “positive” rating for the company. They noted that the move was a valuation call. Finally, Morgan Stanley upgraded shares of Elanco Animal Health from an “equal” rating to a “weight” rating and reduced their price target for the company from $34.00 to $32.00 in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average price target of $33.19.

In other news, CEO Jeffrey N. Simmons purchased 75,750 shares of the company’s stock in a transaction on Wednesday, September 4th. The stock was purchased at an average price of $26.55 per share, with a total value of $2,011,162.50. Following the completion of the purchase, the chief executive officer now directly owns 470,006 shares in the company, valued at approximately $12,478,659.30. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Dawei Li acquired 1,384,717 shares of the business’s stock in a transaction dated Wednesday, September 4th. The stock was purchased at an average price of $1.05 per share, with a total value of $1,453,952.85. Over the last ninety days, insiders purchased 1,475,461 shares of company stock valued at $3,864,853. 0.04% of the stock is owned by insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Winthrop Partners WNY LLC purchased a new position in shares of Elanco Animal Health during the third quarter worth approximately $25,000. Steward Partners Investment Advisory LLC purchased a new stake in shares of Elanco Animal Health in the 2nd quarter valued at $32,000. Institutional & Family Asset Management LLC purchased a new stake in shares of Elanco Animal Health in the 3rd quarter valued at $28,000. Capital Investment Advisory Services LLC boosted its stake in shares of Elanco Animal Health by 1,501.4% in the 2nd quarter. Capital Investment Advisory Services LLC now owns 1,121 shares of the company’s stock valued at $36,000 after purchasing an additional 1,051 shares in the last quarter. Finally, San Francisco Sentry Investment Group CA grew its holdings in shares of Elanco Animal Health by 196.7% during the 3rd quarter. San Francisco Sentry Investment Group CA now owns 1,157 shares of the company’s stock valued at $31,000 after purchasing an additional 767 shares during the last quarter. Institutional investors and hedge funds own 98.43% of the company’s stock.

Elanco Animal Health stock traded down $0.32 during mid-day trading on Tuesday, reaching $27.30. 1,472,303 shares of the company’s stock were exchanged, compared to its average volume of 5,259,906. The business’s fifty day simple moving average is $26.87 and its 200 day simple moving average is $29.67. The company has a quick ratio of 1.67, a current ratio of 3.12 and a debt-to-equity ratio of 0.43. Elanco Animal Health has a one year low of $25.25 and a one year high of $35.46. The firm has a market capitalization of $10.34 billion, a PE ratio of 23.14 and a beta of 0.71.

About Elanco Animal Health

Elanco Animal Health Incorporated, an animal health company, develops, manufactures, and markets products for companion and food animals. The company offers companion animal disease prevention products, such as parasiticide products that protect pets from worms, fleas, and ticks; companion animal therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications; vaccines, nutritional enzymes, and animal-only antibiotics; and a range of food animal products used in ruminant and swine production.

Featured Article: Why is the LIBOR significant?

Get a free copy of the Zacks research report on Elanco Animal Health (ELAN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.